Taken together, modulating the gut microbiota, which may influence both gut-residing and CNS-associated immune cells that produce IL-17A, represents a promising therapeutic strategy for neurological disorders characterized by chronic inflammation. This evidence concerns the gene IL17A and nervous system disorder.